Coherus BioSciences Inc. (CHRS) Plunges 5.53%

Coherus BioSciences Inc. (CHRS) had a rough trading day for Wednesday October 23 as shares tumbled 5.53%, or a loss of $-1.03 per share, to close at $17.59. After opening the day at $18.57, shares of Coherus BioSciences Inc. traded as high as $18.65 and as low as $17.39. Volume was 981,011 shares over 9,518 trades, against an average daily volume of n/a shares and a total float of 69.76 million.

As a result of the decline, Coherus BioSciences Inc. now has a market cap of $1.23 billion. In the last year, shares of Coherus BioSciences Inc. have traded between a range of $23.91 and $8.32, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.

Coherus BioSciences Inc. is based out of Redwood City, CA and has some 257 employees. Its CEO is Dennis M. Lanfear.

Coherus BioSciences Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

error: Content is protected !!